Expression and characterization of human group C rotavirus virus-like particles in insect cells  by Clark, Kristina B. et al.
Virology 387 (2009) 267–272
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roExpression and characterization of human group C rotavirus virus-like
particles in insect cells☆
Kristina B. Clark a, Seh-Ching Lin b, Charles Humphrey c, Kimberly Foytich a, Mathew Esona a, YuhuanWang a,
Merry Liu b, Baoming Jiang a,⁎
a Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia, USA
b Division of Scientiﬁc Resources, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, Georgia, USA
c Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA☆ The ﬁndings and conclusions in this report are tho
necessarily represent the views of CDC.
⁎ Corresponding author. Gastroenteritis and Respira
Stop G04, Centers for Disease Control and Prevention,
Georgia 30333, USA. Fax: +1 404 639 3645.
E-mail address: bjiang@cdc.gov (B. Jiang).
0042-6822/$ – see front matter. Published by Elsevier
doi:10.1016/j.virol.2009.02.023a b s t r a c ta r t i c l e i n f oArticle history: Group C rotavirus (GpC RV)
Received 18 August 2008
Returned to author for revision
9 February 2009
Accepted 17 February 2009





Virus-like particlesis a causative agent of acute gastroenteritis in children and adults. We expressed
the three major capsid proteins VP2, VP6 and VP7 of human GpC RV in baculovirus and demonstrated the
self-assembly of VP2/6/7 or VP6/7 virus-like particles (VLPs) in insect cells. We examined a number of
parameters, including the kinetics of protein synthesis in different cell lines and media, to optimize the most
favorable conditions for the synthesis of recombinant viral proteins and the production of VLPs in Sf9 cells.
Hyperimmune serum to VP2/6/7 and VP6/7 VLPs recognized individual recombinant proteins of human GpC
RV by Western blot analysis. This serum also showed speciﬁc reactivities with the corresponding GpC VLPs
but not GpA RV by using immune electron microscopy (IEM) and enzyme immunoassay (EIA). The ability to
produce an unlimited amount of GpC RV antigen and the availability of high quality antibody will allow us to
develop sensitive and speciﬁc diagnostic assays to better determine the epidemiology and disease burden of
GpC RV in humans.
Published by Elsevier Inc.IntroductionRotaviruses are a diverse set of pathogens classiﬁed into groups A
through G based on the distinct characteristics of the inner capsid
protein, VP6. Among these, group C rotavirus (GpC RV) has been
demonstrated to contribute to outbreaks and sporadic cases of
gastroenteritis in children and adults worldwide (Banyai et al.,
2006; Gabbay et al., 1999; Jiang et al., 1995; Kuzuya et al., 1998;
Nilsson et al., 2000; Otsu, 1998; Phan et al., 2004; Rahman et al., 2005;
Schnagl et al., 2004; Souza et al., 1998; Steyer et al., 2006). While
studies have reported low detection rates of GpC RV in fecal specimens
of children with diarrhea, seroprevalence studies have demonstrated
that this virus is a commonplace pathogen with a much higher
occurrence in adults (Abid et al., 2007; Banyai et al., 2006; Castello
et al., 2002; Cox et al., 1998; Iturriza-Gomara et al., 2004; Nilsson et al.,
2000; Rahman et al., 2005; Riepenhoff-Talty et al., 1997; Schnagl et al.,
2004; Steele and James, 1999).
One possible cause of low GpC RV detection is the lack of adequate
diagnostic tools. While PCR or nested PCR, a frequently employedse of the authors and do not
tory Viruses Lab Branch, Mail
1600 Clifton Road NE, Atlanta,
Inc.technique, may be the gold standard for the detection of viruses, it is
often insensitive for diagnosis of GpC RV due to the instability of viral
capsid proteins and the presence of empty viral particles (Jiang et al.,
1995; Yee et al., 2006; Esona et al., 2008). It is also not an accessible
technique tomany clinical laboratories that are involved in diagnostics
of samples from patients with gastroenteritis. If a more practical and
economical tool, like a GpC RV-speciﬁc enzyme immunoassay (EIA),
was available, testing of large numbers of samples could be performed
to better estimate GpC RV disease burden in humans. Propagation of
the Cowden strain, a prototype porcine GpC RV, has been successful
and antibodies to this virus have been employed for GpC RV
diagnostics (Jiang et al., 1995; Sanchez-Fauquier et al., 2003; Souza
et al., 1998; Terrett and Saif, 1987; Tsunemitsu, Jiang, and Saif, 1992).
While human GpC RV strains detected to date are highly conserved in
their genome and appear to belong to a single VP7 genotype (Jiang
et al., 1996), human and porcine GpC RV strains are generally less
conserved. Therefore, the speciﬁcity and sensitivity of the Cowden-
based EIA for the detection of human GpC RV are questionable.
Progress in the development of a sensitive and speciﬁc EIA for the
detection of GpC RV in human specimens has been stunted because
none of the human GpC strains have been adapted to grow in cell
culture. In order to obtain an adequate supply of antigen and antibody
for use in the development of diagnostic tools, we prepared
recombinant baculoviruses that express major capsid proteins VP2
of the human GpC strain ASP88 and VP6 and VP7 of the human GpC
strain S-1. The strains ASP88 and S-1 were originally detected from
Fig. 1. Kinetics of human GpC RV capsid protein expression in Sf9 (A) or Hi5 (B) cells in different media. Cells were co-infected in stationary ﬂasks with recombinant baculoviruses
expressing VP2, VP6 and VP7, each at an MOI of 1. Infected cultures were harvested daily and supernatants from 0, 3 to 5 dpi were examined on 12% SDS-PAGE, transferred to PVDF
membranes, and exposed to a Cowden-speciﬁc porcine hyperimmune serum. Lanes 1, Cowden strain; 2–5, infected cultures inHyQharvested 0, 3–5 dpi; and 6–9, infected cultures in EX-
CELL harvested at 0, 3–5 dpi. GpC RV VP6 and VP7 are indicated on the right. Molecular markers 54 kDa and 37.5 kDa are indicated by arrows on the left. GpC RV VP2 was not detected.
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respectively (Jiang et al., 1996). The VP7 genes of these two strains
shared high sequence identities with the cognate genes of other
human GpC strains. We sought to express these viral proteins in insect
cells, demonstrate their self-assembly into virus-like particles (VLPs),
and perform biochemical and antigenic characterization. In addition,
we developed a hyperimmune serum speciﬁc to these VLPs and
examined its reactivities with GpA RV and GpC VLPs.
Results
Kinetics of GpC RV protein synthesis in Sf9 and Hi5 cells
Sf9 and Hi5 cells in EX-CELL or HyQ media were infected with GpC
RV VP2, VP6, and VP7 baculovirus recombinants at an MOI of 1 each
and infected cultures were harvested on days 3, 4 and 5. Infected
cultures were clariﬁed and analyzed by Western blot using Cowden-
speciﬁc porcine hyperimmune serum to determine the levels of
proteins expressed and secreted into the supernatant (Fig. 1).
Expression of human GpC RV VP6 and VP7 increased with time, with
the highest levels seen at 4 or 5 days post infection (dpi) in Sf9 and Hi5
cells. Use of EX-CELL media resulted in higher expression of rotavirus
proteins in both cell lines. Sincewe observed higher protein expression
in EX-CELL media and similar levels of protein expression in Sf9 and
Hi5 cells, we chose to use Sf9, the most commonly employed cell line,
and EX-CELL 420 for subsequent production of GpC RV proteins. GpC
RV VP2 was not detected with the hyperimmune serum used possibly
due to a lack of sensitivity or a lack of cross-reactivity between the
human GpC RV VP2 and the porcine hyperimmune serum.
Self-assembly and characterization of GpC RV VLPs
Superinfections of Sf9 cells with recombinant baculoviruses
expressing VP2, VP6 and VP7 at an MOI of 1 each resulted in theFig. 2. Electron micrographs of human GpC RV VLPs. VLPs were puriﬁed from cultures of Sf9
VP6, and VP7 at an MOI of 1 each (A) or VP6 and VP7 at an MOI of 1.4 each (B). The porcine
stained with 5% ammonium molybdate–1% trehalose. Bar=100 nm.formation of intact GpC RV VLPs that have the characteristic
structure of typical rotavirus particles (Fig. 2A). Sf9 cells were also
superinfected with three recombinant baculoviruses at various
MOIs (0.1, 0.2, 1 and 2 each) in order to optimize conditions for
VLP production. EM analysis of the supernatants demonstrated
better VLP formation in superinfections implemented at higher
MOIs (data not shown). In addition, superinfections were
performed without recombinant baculovirus expressing VP2 at an
MOI of 1.4 each and VLP formation was demonstrated (Fig. 2B).
VP2/6/7 VLPs and VP6/7 VLPs resembled in morphology Cowden
virions (Fig. 2C).
We performed two experiments to examine and compare the
yields of VP2/6/7 and VP6/7 VLPs in Sf9 cells using Excell-420
medium. We observed slightly higher yield (38.4 μg) for VP6/7 VLPs
than that (23.6 μg) for VP2/6/7 VLPs in 100 ml of cultures. Because
VP2 appeared to be non essential for the formation, stability, and yield
of VLPs, subsequent experiments were performed in the absence of
this recombinant baculovirus.
Antigenic reactivity of GpC RV antibody
Polyclonal antibody to human GpC RV was produced by injecting
VP2/6/7 and VP6/7 VLPs into a rabbit. Prior to immunization, rabbit
CD94 had no antibody to GpA or GpC RV and after inoculations
developed a high antibody titer to GpC RV (Table 1). In controls, rabbit
CD8, which was immunized with RRV, gave a strong positive response
to GpA RV, whereas rabbit 8807A, which was naturally infected with a
lapine GpA RV and immunized with porcine GpC RV Cowden, had
similar antibody titers to GpA and GpC RV antigens. The hyperimmune
serum to human GpC VLPs was further utilized to improve our current
EIA that employed only porcine hyperimmune sera. This new assay
proved to speciﬁcally detect GpC RV antigens (VLPs and Cowden) but
did not react with control samples, such as MA104, Sf9 cells, or GpA RV
RRV (data not shown).cells in EX-CELL 420 medium that were infected with recombinant baculoviruses VP2,
Cowden particles in MA104 cells are shown for comparison (C). VLPs and virions were
Table 1
Antibody titers of hyperimmune sera to GpA and C rotaviruses
Rabbit Rotavirus Antigen Reciprocal of IgG titer
Group A (RRV) Group C (VLPs)
pre post pre post
CD94 GpC VLPs b100 b100 b100 51,200
CD8 GpA RRV ND 25,600 ND b100
8807A GpC Cowden & GpA ND 1,600 ND 3,200
Rabbit sera were tested and antibody titers were determined as described in the text.
Pre, pre-immunization serum. Post, post-immunization serum. ND, not determined.
Fig. 3. Identiﬁcation of the major structural viral proteins in human GpC RV VLPs. Panel
A: Cowden-infected MA104 cell lysates (lane 1), puriﬁed VP2/6/7 VLPs (lane 2) and
VP6/7 VLPs (lane 3) were separated on a 10% SDS-PAGE and analyzed by Western blot
using the rabbit hyperimmune serum to human GpC RV VLPs. Panel B: Cowden-infected
MA104 cell lysates (lane 1) and human VP2/6/7 VLPs (lane 2) were analyzed by using a
Cowden-speciﬁc porcine hyperimmune serum. For Western blot, proteins were
transferred to PVDF membranes and incubated with rabbit or porcine hyperimmune
serum. GpC RV VP2, VP6 and VP7 are indicated on the left.
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VP6/7 VLPs were examined by Western blot analysis (Fig. 3).
Recombinant proteins VP2, VP6 and VP7 were detected in VP2/6/7
VLPs and VP6 and VP7 were identiﬁed in VP6/7 VLPs by using the
rabbit hyperimmune serum to human GpC VLPs, indicating that these
capsid proteins were antigenic (Fig. 3A). Only VP6 of the porcine
Cowden strain was detected with this hyperimmune serum, suggest-
ing a lower cross-reactivity between the human and porcine strains. In
controls, VP2, VP6 and VP7 of the Cowden strain were all detected by
using a Cowden-speciﬁc hyperimmune serum, whereas only VP6 of
human GpC VP2/6/7 VLPs was detected (Fig. 3B).
We further characterized human GpC RV VP6/7 VLPs by examining
their antigenic properties with IEM using rabbit hyperimmune sera to
GpA RRV and GpC VLPs (Fig. 4). GpC-speciﬁc antibody speciﬁcally
reacted with human GpC VLPs but not with GpA RV RRV. GpA RV
antibody exhibited speciﬁc reactivity with GpA RRV but not with GpC
VLPs. These results indicate the occurrence of group-speciﬁc inter-
actions between rotavirus antigen and antibody and the lack of cross-
reactivity between GpA and GpC RV.
Discussion
Characterization of GpC RV has only been accomplished to date
with porcine and bovine strains that can be grown in cell culture (Saif
et al., 1988; Tsunemitsu et al., 1991). The present study is the ﬁrst to
demonstrate the self-assembly of human GpC RV VLPs in insect cells
and to characterize their properties. These GpC RV VLPs enabled us to
manufacture a more speciﬁc hyperimmune serum to GpC RV thanwas
previously available. Possession of both high quality antigen and
antibody will allow us to develop speciﬁc and sensitive diagnostic
tools and may lead to an increased level of detection of GpC RV in
human specimens and the discovery of new strains with more
sequence diversity.
Thebaculovirus systemwas chosen toproduceGpCRVVLPsbecause
it has been commonly employed for the expression of GpA RV proteins
in functional analysis studies and vaccine development (Berois et al.,
2003; Charpilienne et al., 2002; Ciarlet et al., 1998; Jiang et al., 1999;
Mena, Ramirez, and Palomares, 2006; Zeng et al.,1998). The production
of those rotavirus proteins is often performed in Hi5 or Sf9 cells with
MOIs of baculovirus recombinants as high as 5 or more using culture
media supplemented with fetal bovine serum (Berois et al., 2003;
Charpilienne et al., 2002; Crawford et al., 1994; Zeng et al., 1998). In our
present study, we optimized the growth conditions and demonstrated
the production of high quality VLPs in Sf9 cells at a lower MOI using
serum-freemedia. Our ﬁndings that insect cells propagated in different
cell culture media can result in the varying yields of GpC RV VLPs agree
with those reported for GpA RV (Jiang et al., 1998).
For GpA RV, VLPs produced in insect cells comprise of one, two, or
multiple proteins (Crawford et al., 1994; Madore et al., 1999; Zeng
et al., 1996). Because VP2 is a scaffolding protein, it is widely believed
to contribute to the formation of stable VP2/6, VP2/6/7, and VP2/4/
6/7 VLPs. Two studies described the synthesis of VP6/7 VLPs and
demonstrated that VP2 was not required for their assembly (Madore
et al., 1999; Sabara et al., 1991). In the present study, we demonstratedstable formation of VP6/7 VLPs of human GpC RV, again indicating
that VP2 is not required. We further demonstrated comparable yields
and stability of VP6/7 VLPs and VP2/6/7 VLPs. Nevertheless, further
studies are needed to examine the interactions of VP2 with other
proteins and better deﬁne its role in the assembly of human GpC RV
VLPs.
We performed biochemical characterization of GpC RV VLPs and
demonstrated that recombinant capsid proteins VP2, VP6 and VP7 in
assembled particles are the correct size. These proteins were highly
antigenic, as demonstrated by their reactivities with homologous
rabbit hyperimmune serum to human GpC RV VLPs by EIA, Western
blot and IEM. Of note, these recombinant capsid proteins showed
lower cross reactivities with a porcine polyclonal antibody to the
Cowden strain. These recombinant proteins showed no antigenic
reactivities with rabbit hyperimmune serum to GpA RV, again
conﬁrming a lack of antigenic relationship between GpA and GpC
RV (Jiang et al., 1990).
Our ﬁndings have several implications. Despite the low yields of
GpC VLPs, the availability of high quality antigen will allow us to
produce highly speciﬁc monoclonal antibodies and to develop
sensitive and speciﬁc diagnostic assays for the detection of GpC RV
infection in humans. The new diagnostic tools should enhance the
detection of GpC RV in fecal specimens and lead to a clearer
understanding of the epidemiology and disease burden of this virus
in humans. GpC VLPs may make it possible to perform structure–
function analyses and investigate the biology of human GpC RV. These
VLPs may have potential to serve as a potent immunogen in a subunit
vaccine against GpC RV infection in the future.
Materials and methods
Cloning and construction of recombinant baculoviruses
Segment 5 that encodes VP6 of the human GpC RV strain S-1 was
ampliﬁed by RT-PCR with BMJ44 (5′-AGCCACATAGTTCACATTTC-3′)
and BMJ141 (5′-ATCTCATTCACAATGGATG-3′) (Sanchez-Fauquier et al.,
2003). Segment 8 encoding VP7 of the strain S-1 was ampliﬁed by RT-
PCR using primers BMJ13 (5′-AGCCACATGATCTTGTTT-3′) and BMJ14
(5′-GGCATTTAAAAAAGAAGA-3′) (Jiang et al., 1995). Because ampliﬁ-
cation of the S-1 gene 2 was not successful, segment 2 encoding VP2 of
the strain ASP88 was ampliﬁed by RT-PCR with BMJ197 (5′-TCGAGGA-
CAAATCGTCCAAG-3′) and BMJ180 (5′-AGCCACAGAGTTTGAGGT-C-3′).
Fig. 4. Immune electronmicrographs of humanGpCRVVP6/7VLPs and simianGpARVRRV. IEMwas carried out as described in the text. Panels A, GpC RVVLPswithGpC-speciﬁc rabbit
hyperimmune serum; B, GpC RVVLPswithGpA-speciﬁc rabbit hyperimmune serum; C, GpA RVwith GpC-speciﬁc rabbit hyperimmune serum; andD, GpA RVwith GpA-speciﬁc rabbit
hyperimmune serum; GpC RV VLPs were speciﬁcally labeled with GpC-speciﬁc antibody and GpA RVs were heavily coated with GpA-speciﬁc antibody. Bar=100 nm.
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VP7 was previously described (Jiang et al., 1996). Full-length DNA
fragments of the ASP88 gene 2 and the S-1 gene 5 were cloned into
vector pVL1393 and transfectionswere performedwith the Bac-N-Blue
transfection kit (Gibco, Grand Island, NY). Baculovirus constructs were
passaged twice in Spodoptera frugiperda 9 (Sf9) cells, plaque puriﬁed,
and then ampliﬁed for two more passages in serum-free HyQ SFX-
INSECT media (Hyclone, Logan, UT).
Cells and superinfections
Sf9 or High Five (Hi5) insect cells were obtained from Invitrogen
(Carlsbad, CA), grown and maintained in EX-CELL 420 or 405 media
(Sigma, Lenexa, KS) or HyQ media in shaker ﬂasks at 27 °C. Sf9 and
Hi5 cells were subcultured every 3 or 4 days at a concentration of
1×106 cells/ml and 5×105 cells/ml, respectively. Superinfections
were performed by seeding Sf9 cells in HyQ or EX-CELL 420 and Hi5
cells in HyQ or EX-CELL 405 into T150 ﬂasks at a concentration of
3×105 cells/ml. Baculovirus constructs (rVP2, rVP6 and rVP7) were
added at a multiplicity of infection (MOI) of 1 each. Superinfections
were carried out without proteinase inhibitors and infected cultures
were harvested at day 5. For the production of VLPs, superinfections
were performed in suspension culture by seeding Sf9 cells in EX-CELL
420 into Fernbach ﬂasks at a concentration of 1×106 cells/ml.
Baculovirus recombinants were inoculated 1 day later at an MOI of
1.0–1.4 each and harvested at day 4.
Western blot
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was carried out with 10% separating and 5% stacking gels using
the Laemmli discontinuous buffer system (Laemmli, 1970). Sampleswere heated at 97 °C for 5 min with 10% β-mecaptoethanol prior to
loading and then electrophoresed. Proteins were transferred to a
polyvinylidene ﬂuoride (PVDF) membrane in transfer buffer (25 mM
Tris [pH 8.3], 192 mM glycine, 10% methanol). After blocking with 10%
blotto in 0.01 M phosphate buffered saline [pH 7.5] supplemented
with Tween 20 (PBS-T) for 1–2 h at room temperature, membranes
were incubated with porcine hyperimmune serum (1:2000) to
Cowden or rabbit hyperimmune serum (1:20,000) to human GpC
VLPs in 5% blotto in PBS-T overnight at 4 °C. Membranes were washed
in PBS-T, incubated with horseradish peroxidase (HRP) goat anti-pig
(1:142,000) (KPL, Gaithersburg, MD) or HRP-goat anti-rabbit
(1:20,000) (Pierce, Rockford, IL) in 5% blotto. GpC RV proteins were
visualized with Supersignal West Femto Maximum Sensitivity Sub-
strate Kit (Pierce, Rockford, IL) by exposing membranes to ﬁlm and
processing with medical ﬁlm processor SRX-101A (Konica Minolta,
Jakarta, Indonesia).
Puriﬁcation of VLPs
Infected cell cultures were clariﬁed twice at 15,344 ×g for 30 min at
4 °C with a JA-14 rotor in J2-MC centrifuge. Clariﬁed supernatants were
layered over 35% sucrose cushions and centrifuged for 2 h at 107,000 ×g
(4 °C) with the SW32Ti rotor in an Optima L-80 XP Ultracentrifuge
(Beckman Coulter, Fullerton, CA). Pellets were resuspended in TNC
buffer (10mM Tris [pH 7.4], 140mMNaCl, 5 mM CaCl2), re-clariﬁed in a
microcentrifuge and treated twice sequentially with an equal volume of
Vertrel (Miller-Stephenson, Danbury, CT). Samples were centrifuged
10 min at 2095 ×g (4 °C) with a SX4750A rotor in the Allegra X-12R
tabletop centrifuge (Beckman Coulter, Fullerton, CA). The aqueous layer
was overlayed on top of a CsCl solution (1.2738 g/ml) and centrifuged
17–18 h at 111,000 ×g (4 °C) with the SW40Ti rotor. Fractions that
contained VLPs were collected, diluted in TNC, and pelleted out by
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were resuspended inHanks balanced salt solution (GIBCO, Grand Island,
NY) supplemented with 10% sorbitol. The protein concentration of
puriﬁedVLPswasmeasured by theBradfordmethod usingbovine IgG as
standards (Bio-Rad, Hercules, CA).
Production of antiserum to GpC VLPs
Rabbits (Covance, Denver, Pennsylvania) were screened for the
presence of GpA and C RV antibodies by antigen capture EIA prior to
immunization. Rabbit CD94, which tested negative for GpA and C
antigens, was selected and injected subcutaneously with 50 μg of
puriﬁed human GpC RV VLPs formulated in Freud's complete
adjuvant. Subsequent doses formulated with Freud's incomplete
adjuvant were administered in 3-week intervals after the previous
injection. Five injections in total were administered. The ﬁrst bleed
was 10 days after dose two and all subsequent bleeds were scheduled
3 weeks after the previous bleed. All bleeds tested positive for GpC RV
antibody and were pooled.
Electron microscopy and immunoelectron microscopy
GpC RV VLPs were examined by electron microscopy (EM) and
immunoelectron microscopy (IEM) as previously described with
modiﬁcations (Harris et al., 2006; Milne,1993). Brieﬂy, 5% ammonium
molybdate-1% trehalose in water [pH 6.95] was used to provide
negative contrast on specimens adsorbed to nickel formvar-carbon
ﬁlmed grids (Harris et al., 2006). Each grid was pre-treated with 1%
alcian blue 8GX in water to enhance hydrophilicity and provide
cationic charges to the ﬁlm surface prior to applying specimens. IEM
was done by mixing 1 μl of puriﬁed human GpC RV VLPs or GpA RV
rhesus rotavirus (RRV) with 1 μl of rabbit hyperimmune serum to GpA
RV (CD8) or GpC RV VLPs (CD94) diluted 1:500 and applying to nickel
formvar-carbon coated grids. After incubation for 0.5–1 h, the grids
were blotted with ﬁlter paper, rinsed with 0.1 M Tris buffer
supplemented with 0.4% acetylated bovine serum albumin (Aurion,
Hatﬁeld, Pennsylvania), and incubated for 30 min with goat anti-
rabbit secondary antibody conjugated to 6 nm colloidal gold (1:20).
Grids were rinsed twice with Tris buffer without bovine serum
albumin and with deionized water, blotted, stained with ammonium
molybdate–trehalose, and viewed within an Technai BioTwin trans-
mission electron microscope (FEI, Hillsboro, OR) at 120 kV accelerat-
ing voltage. Images were captured digitally with a 2K×2K digital
camera (AMT, Danvers, MA).
EIAs
96-well plateswere coated with 100 μl supernatant fromGpA RRV-
infected MA104 cell cultures or GpC VLPs in recombinant baculovirus-
infected Sf9 cell cultures diluted (1:100) in coating buffer (15 mM
Na2CO3, 35 mM NaHCO3 [pH9.6]) and incubated overnight at 37 °C.
Plates were washed with PBS-T and then blocked with 150 μl of 5%
blotto for 1 h at 37 °C. Plates were washed and then incubated with
100 μl of serially diluted hyperimmune serum from rabbits CD94, CD8,
and 8807A in diluent (1% blotto and 0.5% polyoxethylene ether W1 in
PBS) for 2 h at 37 °C. Rabbit CD8 was immunized with puriﬁed GpA RV
RRV, whereas rabbit 8807A was immunized with puriﬁed GpC RV
Cowden but also was positive for GpA RV, indicating a natural
infection with a lapine rotavirus. Plates were washed and then
incubated with HRP-goat anti-rabbit IgG (KPL, Gaithersburg, MD)
diluted (1:3000) in diluent for 1 h at 37 °C. Plates were washed 6
times with PBS-T and then reacted with 100 μl of tetramethyl
benzidine for 10 min. Reactions were stopped with 100 μl of 1 N HCl
and plates were read at Abs450. Antibody titer was deﬁned as the
reciprocal of the highest dilution of serum giving a net optical density
(OD) value (OD with virus minus OD with blotto) above 0.1.Acknowledgments
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